JP2023504205A - 角膜病変の治療のための生体分子 - Google Patents

角膜病変の治療のための生体分子 Download PDF

Info

Publication number
JP2023504205A
JP2023504205A JP2022534665A JP2022534665A JP2023504205A JP 2023504205 A JP2023504205 A JP 2023504205A JP 2022534665 A JP2022534665 A JP 2022534665A JP 2022534665 A JP2022534665 A JP 2022534665A JP 2023504205 A JP2023504205 A JP 2023504205A
Authority
JP
Japan
Prior art keywords
corneal
dha
rvd6si
composition
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504205A5 (enExample
Inventor
アイデー バザン
ニコラス ジー． バザン
サン エル． ファム
ボッキョオ ジュン
ニコス エー． ペタシス
Original Assignee
ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ
ユニバーシティ オブ サザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ, ユニバーシティ オブ サザン カリフォルニア filed Critical ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ
Publication of JP2023504205A publication Critical patent/JP2023504205A/ja
Publication of JP2023504205A5 publication Critical patent/JP2023504205A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022534665A 2019-12-09 2020-12-09 角膜病変の治療のための生体分子 Pending JP2023504205A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945580P 2019-12-09 2019-12-09
US62/945,580 2019-12-09
PCT/US2020/064042 WO2021119146A1 (en) 2019-12-09 2020-12-09 Biomolecule for treatment of corneal pathologies

Publications (2)

Publication Number Publication Date
JP2023504205A true JP2023504205A (ja) 2023-02-01
JP2023504205A5 JP2023504205A5 (enExample) 2023-12-18

Family

ID=76330542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534665A Pending JP2023504205A (ja) 2019-12-09 2020-12-09 角膜病変の治療のための生体分子

Country Status (8)

Country Link
US (2) US20230019568A1 (enExample)
EP (1) EP4072578A4 (enExample)
JP (1) JP2023504205A (enExample)
CN (1) CN115038434A (enExample)
AU (1) AU2020402031A1 (enExample)
BR (1) BR112022011276A2 (enExample)
CA (1) CA3161233A1 (enExample)
WO (1) WO2021119146A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4311554A1 (en) * 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500568A (ja) * 2007-10-12 2011-01-06 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
WO2014032026A1 (en) * 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
AU2013259503B2 (en) * 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2022056311A1 (en) * 2020-09-10 2022-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500568A (ja) * 2007-10-12 2011-01-06 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
WO2014032026A1 (en) * 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Also Published As

Publication number Publication date
US20230019568A1 (en) 2023-01-19
CA3161233A1 (en) 2021-06-17
BR112022011276A2 (pt) 2022-09-06
EP4072578A1 (en) 2022-10-19
AU2020402031A1 (en) 2022-06-30
WO2021119146A1 (en) 2021-06-17
EP4072578A4 (en) 2024-01-10
CN115038434A (zh) 2022-09-09
US20260224521A1 (en) 2026-08-06

Similar Documents

Publication Publication Date Title
Chu et al. Inflammation mechanism and anti-inflammatory therapy of dry eye
Xie et al. Transforming growth factor-β1 protects against LPC-induced cognitive deficit by attenuating pyroptosis of microglia via NF-κB/ERK1/2 pathways
Bernal‐Chico et al. Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells
Avunduk et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study
de Paiva et al. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye
Colligris et al. Recent developments on dry eye disease treatment compounds
Zhang et al. Valproate protects the retina from endoplasmic reticulum stress-induced apoptosis after ischemia–reperfusion injury
Pham et al. Novel RvD6 stereoisomer induces corneal nerve regeneration and wound healing post-injury by modulating trigeminal transcriptomic signature
JP6574769B2 (ja) 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
Guo et al. Spermidine alleviates severity of murine experimental autoimmune encephalomyelitis
Georgiou et al. Neuroprotective effects of omega-3 polyunsaturated fatty acids in a rat model of anterior ischemic optic neuropathy
Zhang et al. Effects of pranoprofen on aqueous humor monocyte chemoattractant protein-1 level and pain relief during second-eye cataract surgery
Luo et al. SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice
Coppey et al. Enriching the diet with menhaden oil improves peripheral neuropathy in streptozotocin-induced type 1 diabetic rats
Kenchegowda et al. Involvement of pigment epithelium-derived factor, docosahexaenoic acid and neuroprotectin D1 in corneal inflammation and nerve integrity after refractive surgery
CA3136137A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
Skalicky et al. New agents for treating dry eye syndrome
CN114555107A (zh) 用于干眼病的tsg6多肽片段
Dieckmann et al. A single administration of OC-01 (varenicline solution) nasal spray induces short-term alterations in conjunctival goblet cells in patients with dry eye disease
Zhou et al. Targeting α7 nicotinic acetylcholine receptor for modulating the neuroinflammation of dry eye disease via macrophages
Nanì et al. Pharmacological inhibition of N-Acylethanolamine acid amidase (NAAA) mitigates intestinal fibrosis through modulation of macrophage activity
Lee et al. The repurposing of nitazoxanide for psoriasis treatment exerts therapeutic effects through skin metabolic reprogramming
Wang et al. Melatonin Ameliorates Circadian Disruption‐Associated Dry Eye via Modulation of BMAL1‐REV‐ERBα‐IL‐17 Axis and Ocular Surface Microbiota Homeostasis
Pacheco et al. Neuroprotective effect of exogenous galectin-1 in status epilepticus
US20230019568A1 (en) Biomolecule for treatment of corneal pathologies

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250526